Study of Indoleamine 2,3-dioxygenase Activity, Serum Levels of Cytokines, BDNF, BH4 and Mirtazapine Efficacy in Fibromyalgia Syndrome
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study aims to investigate the anti-nociceptive biogenic amine (serotonin [5-hydroxytryptamine; 5-HT], norepinephrine [NE], dopamine [DA], and their metabolites) status, and serum levels of cytokines, BDNF and BH4 in Thai fibromyalgia syndrome (FMS) patients compared with a representative Thai population. The efficacy and the tolerability of mirtazapine as monotherapy for FMS will also be assessed. In addition, proof of concept of the indoleamine 2,3-dioxygenase (IDO) activity in FMS will be conducted.
The study will be divided into three parts. In part I, FMS patients of Thai ethnicity will be examined to determine the blood and/or urinary level of anti-nociceptive biogenic amines, cytokines, BDNF and BH4 by comparison with the demographically matched, but unrelated, healthy normal controls (HNC). In part II, the FMS subjects from part I study will be randomized to blinded therapy with mirtazapine or identical appearing placebo. There will be three treatment groups (N=1:1:1) to accommodate two dosages of mirtazapine (15 mg, 30mg) and placebo given before bedtime. Pill counts at baseline and at follow-up visits will document compliance. Standard outcome instruments (translated and validated in Thai language) will be used at baseline and at each of the follow-up visits. The co-primary outcome variable will be the changes in the pain visual analog scale (PVAS) score and pain responders (>= 30% PVAS reduction). Secondary clinical outcome variables of interest will include depression, insomnia, anxiety, physical function, morning stiffness, patient global assessment of disease status, patient global impression of change, fibromyalgia impact questionnaire (FIQ, quality of life and adverse experience. The changes of biogenic amine and IGF-1 concentrations in blood and/or urine with the treatment will be examined as the secondary biochemical measures. In part III, the IDO activity of depressed FMS, non-depressed FMS and HNC will be compared. Moreover, the effect of mirtazapine treatment on the IDO activity in depressed and non-depressed FMS patients will be assessed.
Study hypothesis
- Anti-nociceptive biogenic amine levels in Thai FMS patients are lower than in Thai healthy normal control.
- Higher IDO activity could be observed in FMS patients.
- Higher cytokines could be observed in FMS patients.
- Higher BDNF could be observed in FMS patients.
- Lower BH4 could be observed in FMS patients.
- Mirtazapine is effective in FMS treatment.
| Condition | Intervention | Phase |
|---|---|---|
|
Fibromyalgia Syndrome |
Drug: mirtazapine Drug: placebo |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver) Primary Purpose: Treatment |
| Official Title: | Study of Anti-nociceptive Biogenic Amine Status, Indoleamine 2,3-dioxygenase Activity, Serum Levels of Cytokines, BDNF, BH4 and Mirtazapine Efficacy in Thai Fibromyalgia Syndrome Patients. |
- The primary outcome measure for part II of this study will be "change from baseline in the severity of the pain visual analog scale (PVAS) score" and pain responders (>= 30% PVAS reduction). [ Time Frame: day 7, 21, 35, 63, 91 (day 0 = first day of starting expected dose) ] [ Designated as safety issue: No ]
- Depression, sleep quality, patient global assessment of disease status, FIQ, PGIC, quality of life, adverse events [ Time Frame: day 7, 21, 35, 63, 91 (day 0 = the day of starting expected dose) ] [ Designated as safety issue: Yes ]
| Enrollment: | 80 |
| Study Start Date: | December 2008 |
| Study Completion Date: | December 2011 |
| Primary Completion Date: | October 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Placebo Comparator: placebo
placebo
|
Drug: placebo
placebo
Other Name: placebo
|
|
Placebo Comparator: mirtazapine 15
mirtazapine 15 mg
|
Drug: mirtazapine
mirtazapine 15 mg or 30 mg tablet daily at bedtime for 13 weeks
Other Name: Remeron
|
|
Placebo Comparator: mirtazapine 30
mirtazapine 30mg
|
Drug: mirtazapine
mirtazapine 15 mg or 30 mg tablet daily at bedtime for 13 weeks
Other Name: Remeron
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria for randomized controlled trial:
- male or female outpatients > 18 years of age, descended from Thai parents
- meet criteria for FMS as defined by the American College of Rheumatology 1990
- have a score of > 4 on the pain visual analog scale (PVAS) score at screening
Exclusion Criteria:
- any severe or unstable physical or psychiatric disorder
- inflammation or injury or trauma in the previous month
- substance abuse within the past year
- serious suicide risk
- pregnancy or breastfeeding
- subject has an allergic reactions to mirtazapine or any of its constituents or severe allergic reactions to multiple medications
- comorbid inflammatory rheumatic diseases
- Use of medications or herbal agents with CNS activity
- regular use of analgesics with the exception of acetaminophen up to 2 gram/day
- chronic use of sedatives/hypnotics
- unable to discontinue medications that may affect the study results (all antidepressants, mood stabilizers, antipsychotics, sleep aids such as hypnotics, tranquilizers, sedating antihistamine and benzodiazepines, all analgesics including anticonvulsants, muscle relaxants, stimulant medications such as dextroamphetamine and methylphenidate, any other medications taken by the subject for the treatment of fibromyalgia
- unable to attend the follow-up schedule of the study
- not agree with avoidance or stable maintenance of unconventionalor alternative therapies, such as Thai traditional massage
Contacts and Locations| Thailand | |
| Siriraj Hospital, Mahidol University | |
| Bangkoknoi, Bangkok, Thailand, 10700 | |
| Principal Investigator: | Suwimon Yeephu | Faculty of Pharmacy Mahidol University |
| Principal Investigator: | Saithip Suttiruksa, Master | Faculty of Pharmacy, Mahidol University |
More Information
No publications provided
| Responsible Party: | Suwimon Yeephu, Faculty of Pharmacy, Mahidol University |
| ClinicalTrials.gov Identifier: | NCT00919295 History of Changes |
| Other Study ID Numbers: | 323/2551(EC4) |
| Study First Received: | June 11, 2009 |
| Last Updated: | July 24, 2012 |
| Health Authority: | Thailand: Ethical Committee |
Keywords provided by Mahidol University:
|
Fibromyalgia syndrome mirtazapine randomized controlled trial pilot study |
Additional relevant MeSH terms:
|
Fibromyalgia Myofascial Pain Syndromes Muscular Diseases Musculoskeletal Diseases Rheumatic Diseases Neuromuscular Diseases Nervous System Diseases Mirtazapine Mianserin Antidepressive Agents, Tricyclic Antidepressive Agents Psychotropic Drugs Central Nervous System Agents Therapeutic Uses |
Pharmacologic Actions Histamine H1 Antagonists Histamine Antagonists Histamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Adrenergic alpha-Antagonists Adrenergic Antagonists Adrenergic Agents Serotonin Antagonists Serotonin Agents Antidepressive Agents, Second-Generation |
ClinicalTrials.gov processed this record on June 18, 2013